2012 revenue: $9.82 billion
2011 revenue: $9.7 billion
Year in review: GE Healthcare, the medical equipment division of the global healthcare conglomerate GE ($GE), capped 2012 with a steady revenue growth and a number of corporate coups. Among the biggest: The company licensed its investigative Alzheimer's imaging agent flutemetamol to Merck ($MRK). Flutemetamol is designed to be injected into patients before PET scans and detects beta-amyloid deposits in the brain, a major sign of Alzheimer's horrible advance. And Merck will test it with certain trial participants taking MK-8931, a hoped-for blockbuster Alzheimer's treatment. The imaging agent has already shown promise as far as Phase III, detecting beta amyloid with a 75% to 100% sensitivity and 99% to 100% specificity. Looking ahead into 2013, GE Healthcare continues to work on building imaging and other business lines. The company recently committed to the NFL, for example, to invest at least $50 million in a bid to develop concussion-detecting imaging technology.
GE licenses Alzheimer's imaging agent to Merck
GE, NFL to pour $50M into concussion imaging tech